Humana ends lower as traders weigh Medicare star-rating news
Humana shares ended Thursday at $387.12, down 2.37% from the prior close, with a neutral daily chart and weaker hourly signals. The stock traded below its 20-session EMA but above its 50-session EMA, while daily RSI was under 50 and the daily MACD stayed positive. After the close, reports said Humana's largest Medicare Advantage contract was upgraded to 4 stars and that 95% of its Medicare members are in 4-star-or-better plans.
Humana finished Thursday at $387.12, down 2.37% from the prior close of $396.51. The session ranged from $375.86 to $399.19 after opening at $396.03, with volume of 2,658,300 shares. The stock closed beneath its 20-session EMA of $390.48 but above its 50-session EMA of $385.1.
Daily RSI was 48.33, while the MACD histogram remained positive at 0.79. Hourly signals were weaker: price sat below all three hourly EMAs, hourly RSI was 44.05, and the hourly MACD line was below its signal. After the bell, reports said Humana’s biggest Medicare Advantage agreement, covering more than 2 million members, rose from 3.5 to 4 stars, and 95% of its Medicare membership sat in plans rated at least four stars.
The reported star-rating upgrade could affect Humana’s Medicare Advantage members, as higher ratings may influence plan perception and enrollment choices. Investors may reassess risk after the post-close news, though the market reaction was not yet reflected in Thursday’s close. Broader society could feel indirect effects if plan quality signals shape access or confidence, but the immediate impact is likely concentrated among beneficiaries and shareholders.